Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use

Hybridoma

Volumn 26, Issue 6, 2007, Pages 363-372

  Moffett, Serge ^a   Mélançon, Dominic ^a   DeCrescenzo, Gregory ^b   St Pierre, Caroline ^a   Deschénes, François ^a   Saragovi, H Uri ^a   Gold, Phil ^a   Cuello, A Claudio ^a  

^a ProScan Rx Pharma Inc   (Canada)

^b ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; GLYCYLLYSYLSERYLLEUCYLTYROSYLGLUTAMYLSERYLTRYPTOPHYLTHREONYLLYSYLLYSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 17G1; MONOCLONAL ANTIBODY PSMA; PEPTIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL DEATH; CELL LINE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DIAGNOSTIC VALUE; DRUG DELIVERY SYSTEM; DRUG TARGETING; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, SURFACE; BINDING SITES, ANTIBODY; CELL LINE, TUMOR; EPITOPES; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; HYBRIDOMAS; K562 CELLS; MALE; MICE; MICE, INBRED BALB C; TUMOR MARKERS, BIOLOGICAL;

MURINAE; MUS;

EID: 37549060611     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2007.0522     Document Type: Article

References (58)

1. Monitori R: Prognostic factors in prostate cancer. BMJ 2001; 322:378-379.
2. Nelson WG, De Marzo AM, and Isaac WB: Prostate cancer. N Engl J Med 2003;349:366-381.
3. Chang SS: Overview of prostate-specific membrane antigen. Rev Urol 2004;6:S13-S18.
4. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Wang CY, et al: Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006;30:628-636.
5. Bostwick DG, Pacelli A, Blute M, Roche P, and Murphy GP: Prostate-specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer 1997;82:2256-2261.
6. Silver DA, Pellicer I, Fair WR, Heston WDW, and Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
7. Wright GLJ, Haley C, Beckett ML, and Schellhammer PF: Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-28.
8. Marchal C, Redondo M, Padilla M, Caballero J, Rodrigo I, Garcia J, et al: Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Hiol Histopathol 2004;19:715-718.
9. Chang SS: Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 2001;57:1179-1183.
10. Horoszewicz JS, Kawinski E, and Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-936.
11. Israeli RS, Powell T, Fair WR, and Heston WDW: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-230.
12. Schulke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, et al: The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA 2003;100:12590-12595.
13. Luthi-Carter R, Barczak AK, Speno H, and Coyle JT: Molecular characterization of a human brain N-acetylated α-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998;286: 1020-1025.
14. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, et al: Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-1451.
15. Nagao K, Hisatomi H, Hirata H, Yamamoto S, Hikiji K, Yamamoto M, et al: Expression of molecular marker genes in various types of normal tissue: implication for detection of micrometastases. Int J Mol Med 2002;10:307-310.
16. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, and Gaudin PB: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-2681.
17. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vasculature endothelium. Cancer Res 1997;57:3629-3634.
18. Huang X, Bennett M, and Thorpe PE: Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 2004;61:1-11.
19. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, and Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198.
20. Conway RE, Petrovic N, Li Z, Heston WDW, Wu D, and Shapiro LH: Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006;26:5310-5324.
21. Ghosh A, Wang X, Klein E, and Heston WDW: Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res 2005;65:727-731.
22. Feneley MR, Jan H, Granowska M, Mather SJ, Ellison D, Glass J, et al: Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer. Prostate Cancer Prostatic Dis 2000;3:47-52.
23. Khan D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, et al: Radioimmunoscintigraphy with 111-indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490-1495.
24. Murphy GP, Elgamal AA, Troychak MJ, and Kenny GM: Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate 2000;42:315-317.
25. Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, et al: Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 1997;33:281-285.
26. Polascik TJ, Manyak MJ, Haseman MK, Gurganus RT, Rogers B, Maguire RT, et al: Comparison of clinical staging algorithms and 111indium-caproMAb pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 1999;85:1586-1592.
27. Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, and Bakale G: Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000;56:988-993.
28. Raj GV, Partin AW, and Polascik TJ: Clinical utility of indium 111-caproMAb pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002;94:987-996.
29. Troyer J, Feng Q, Beckett M, and Wright G: Biochemical characterization and mapping of the 7E11.C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1995;1:29-37.
30. Liu H, Rajasekaran AK, Moy P, Sae Y, Kim S, Navarro V, et al: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58:4055-4060.
31. Smith-Jones PM, Vallabhajosula S, Goldsmith SJ, Navarro V, Hunter C, Bastidas D, et al: In vitro characterization of radio-labeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000;60:5237-5243.
32. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, and Bander NH: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44:610-617.
33. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, and Bander NH: Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate-specific membrane antigen (PSMA): studies in nude mice. Prostate 2004;58:145-155.
34. Nanus DM, Milowsky MI, Kokontis JM LS, Smith-Jones PM, Vallabhajosula S, Goldsmith SJ, et al: Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate-specific membrane antigen. J Urol 2003;170:S84-S89.
35. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones PM, et al: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate-specific membrane antigen. J Urol 2003;170:1717-1721.
36. Stern PS: Predicting antigenic sites on proteins. Trends Biotechnol 1991;9:163-169.
37. Mahadevan D, and Saldanha JW: The extracellular regions of PSMA and the transferrin receptor contain an aminopeptidase domain: implications for drug design. Protein Sci 1999;8:2546-2549.
38. Bates PA, Kelley LA, MacCallum RM, and Sternberg MJ: Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins 2001(suppl);5:39-46.
39. Cuello AC, and Cote A: Preparation and Application of Conventional and Non-conventional Monoclonal Antibodies. Wiley & Sons, New York, 1993.
40. De Crescenzo G, Grothe S, Tsang M, Zwaagstra J, and O'Connor-McCourt MD: Real-time monitoring of the interactions of transforming growth factor-beta (TGF-beta) isoforms with latency-associated protein and the ectodomains of the TGF-beta type II and III receptors reveals different kinetic models and stoichiometries of binding. J Biol Chem 2001;276:29632-29643.
41. Rich RI, and Myszka DG: Advances in surface plasmon resonance biosensor analysis. Curr Opin Biotechnol 2000;11:54-61.
42. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, et al: Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002;53:9-23.
43. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, et al: An alpha-particle emitting antibody ([213Bi]J591) for radio-immunotherapy of prostate cancer. Cancer Res 2000;60:6095-6100.
44. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston WDW, et al: A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003;14:4835-4845.
45. Tino WT, Huber MJ, Lake TP, Greene TG, Murphy GP, and Holmes EH: Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). Hybridoma 2000;19:249-257.
46. Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, and Wetterauer U: A new generation of monoclonal and recombinant antibodies against cell-adherent prostate-specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006;66:1359-1370.
47. Kato K, Yoshikawa K, Taki T, Shitara K, Nakamura K, Hirota M, et al: Further investigation of the epitope recognized by the new monoclonal antibody 2C9. Int J Urol 2003;10:439-444.
48. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, and Wolfert RL: Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998;58:4787-4789.
49. Brown LG, Wegner SK, Wang H, Buhler KR, Arfman EW, Lange PH, et al: A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts. Prostate Cancer Prostatic Dis 1998;1:208-215.
50. Angeletti RH: Design of usefull peptide antigens. J Biomolec Tech 1999;10:2-10.
51. Davis MI, Bennett MJ, Thomas LM, and Bjorkman PJ: Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci USA 2005;102:5981-5986.
52. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, et al: Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBOL J 2006;25:1375-1384.
53. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabhajosukla S, and Goldsmith SJ: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-677.
54. Rajasekaran AK, Anilkumar G, and Christiansen JJ: Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 2005;288:C975-C981.
55. Nargund V, Al Hashmi D, Kumar P, Gordon S, Otitie U, Ellison D, et al: Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. Br J Urol 2005;95:1232-1236.
56. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, and Bander NH: Radioimmunotherapy of prostate cancer using 90Y- and 177 Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res 2005;11:7195-7200.
57. Patri AK, Myc A, Beals J, Thomas TP, Bander NH, and Baker JRJ: Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Biocon Chem 2004;15:1174-1181.
58. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, et al: Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12:2591-2596.